肠道菌群视角下非酒精性脂肪性肝病的治疗策略

Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota

非酒精性脂肪性肝病(NAFLD)是最常见的慢性肝脏疾病,其疾病谱主要包括非酒精性肝脂肪变、非酒精性脂肪性肝炎(NASH)、肝硬化及肝细胞癌(HCC)。近年研究揭示肠-肝轴与NAFLD发生、发展相关,运动、饮食、微生态制剂、抗生素、粪菌移植、噬菌体等干预措施均可以通过改变肠道菌群缓解NAFLD。本文综述了肠道菌群与NAFLD的关系和作用机制及以调整肠道菌群为NAFLD治疗靶点的研究进展,发现肠道菌群与NAFLD密切相关,调控肠道菌群可作为NAFLD治疗的新靶点,将为临床医师治疗NAFLD提供新的思路和参考。

Nonalcoholic fatty liver disease(NAFLD),the most common chronic liver disease,represents a spectrum of nonalcoholic hepatic steatosis,nonalcoholic steatohepatitis,liver cirrhosis and hepatocellular carcinoma.Recent studies have revealed that the gut-liver axis is associated with the development of NAFLD.Intervention measures such as exercise,diet,microecological preparations,antibiotics,fecal microbiota transplantation and bacteriophage can alleviate NAFLD by improving intestinal microbiota.We reviewed recent advances in the relationship and mechanism between intestinal microbiota and NAFLD as well as treatment of NAFLD targeting the intestinal microbiota,and summarized that intestinal microbiota is closely related to NAFLD,and the regulation of intestinal microbiota can be used as a new target for NAFLD treatment,which will provide new ideas and references for clinicians in the diagnosis and treatment of NAFLD.